DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
about
The Molecular Basis of Pharmacological Chaperoning in Human α-GalactosidaseEvaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.N-Alkyl-, 1-C-Alkyl-, and 5-C-Alkyl-1,5-dideoxy-1,5-imino-(L)-ribitols as Galactosidase Inhibitors.1-Deoxy-D-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines.Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.
P2860
Q27676392-F31B43C6-AB94-4F5F-A4EC-60855B26E334Q33568024-02883F10-E1A8-4E9F-B659-F80FE56CDB1DQ34985010-168837E3-8861-401D-85B6-96805016DFD7Q35007910-63B76CE1-24DF-4435-A0ED-61EF57291F05Q37151058-640BB575-8415-45BF-9FBF-D786D5BDA4B1Q38162958-E05CC1DE-2426-44EF-B4C9-9484809274AEQ38797648-946A39FD-8A4A-4AD6-AD2F-33D9C93B8D56Q38813807-F981CA5B-9963-433E-9EBF-F939447AF162Q39529765-191A4551-4C5E-49F8-B7D5-D9B643D9A4A0Q39692896-6EEA76CE-C067-448B-9D41-06B21677F21FQ53251808-26556A7F-D0DC-484C-BD68-A6C048B6D52AQ54945677-2ACF036C-53AC-45A4-B598-469D0A0B59A3
P2860
DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@en
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@nl
type
label
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@en
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@nl
prefLabel
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@en
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@nl
P2093
P1476
DLHex-DGJ, a novel derivative ...... 1)-gangliosidosis fibroblasts.
@en
P2093
Andreas J Steiner
Arnold E Stütz
Bettina M Pabst
Doris Hofer
Eduard Paschke
Georg Schitter
Katrin Fantur
Tanja M Wrodnigg
P304
P356
10.1016/J.YMGME.2010.03.019
P577
2010-03-28T00:00:00Z